Ophthalmic Drugs Market Size, Share, By Product Type (Prescription Drugs and Over The Counter Drugs), Drug Type (Branded Drugs and Generic Drugs), Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, and Others), Route of Administration (Topical, Local Ocular, and Systemic), Dosage Form (Gels, Eye Solutions and Suspension, Capsules and Tablets, Eye Drops, and Others), Therapeutic Class (Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Anti-VEGF Agents, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Others), and Region - Trends, Analysis, and Forecast till 2035

Ophthalmic drugs market size was valued at USD 41.2 Billion in 2025 and is expected to reach USD 64.5 Billion by 2035, growing at a CAGR of 5.0%

Ophthalmic drugs are pharmaceutical products specifically made to treat conditions that affect the eyes, such as glaucoma, infections, dry eyes, and inflammation; it reduces systemic side effects while offering localized treatment and come in the form of eye drops, ointments, or gels. Ophthalmic drugs are used to treat infections, manage glaucoma, relieve dry eyes, reduce inflammation and pain, help dilate or constrict pupils, lubricate the eyes, and treat conditions such as corneal ulcers and eye allergies, which further propels the market.

Increased healthcare spending and investments in eye care, a rapidly aging population, and the rising frequency of eye illnesses such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome are all contributing factors to the growth of the ophthalmic pharmaceuticals market. Innovations in targeted drug delivery, gene therapy, and sustained release that seek to lessen treatment burden and possibly cure a variety of eye disorders are also driving market growth.  These elements also support the growth of the ophthalmic drugs market.